Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director · CEO and President | March 10, 2022 | March 14, 2022 |
| FEMASYS INCFEMY · Entity 7510 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date March 10, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2032-03-10 | Direct | 375,000 |
Reported balance
After 2022-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-10 · Grant · Acquired 375,000 · Balance 375,000 F1: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
FEMASYS INC
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2033-06-14 | Direct | 17,000 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 17,000 · Balance 17,000 F1: The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on June 14, 2024, assuming continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on June 14, 2024, assuming continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2023 Filed Jun 16, 2023 16:41 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001140361-23-030281 · form4.xml · derivative · entry 1 Kendall Keith J · CIK 0001406834 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on June 14, 2024, assuming continued service. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 11:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001214659-22-003894 · marketforms-55758.xml · derivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 13:39 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-009051 · marketforms-53684.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · Custodian of UTMA account for Anna Kendall Disclosed balance after: 1,000 F1 · kind: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F1 · shares: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 13:39 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-009051 · marketforms-53684.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,149 F1 · kind: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F1 · shares: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 17:10 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-21-003150 · marketforms-51878.xml · derivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-000034 · marketforms-50806.xml · nonDerivative · entry 4 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · Custodian of UTMA account for William Kendall Conner Disclosed balance after: 1,000 F3 · kind: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild William Kendall Conner, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F3 · shares: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild William Kendall Conner, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-000034 · marketforms-50806.xml · nonDerivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,149 F3 · kind: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild William Kendall Conner, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F3 · shares: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild William Kendall Conner, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-000034 · marketforms-50806.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · Custodian of UTMA account for Colin Kendall Disclosed balance after: 1,000 F1 · kind: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Colin Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F1 · shares: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Colin Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-000034 · marketforms-50806.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,149 F1 · kind: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Colin Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F1 · shares: On December 30, 2020, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Colin Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-006104 · marketforms-49164.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 148 | $4.86 | $719.28 |
DisclosureSEC source: 0001214659-20-006104 · marketforms-49164.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,149 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-006104 · marketforms-49164.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 50,000 | $5.11 | $255,310.00 |
DisclosureSEC source: 0001214659-20-005427 · marketforms-48972.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,964 F1 · kind: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 18, 2020 in order to satisfy the tax obligations of the reporting person resulting from the (i) conversion of the reporting person's then existing performance-based equity interests in the Company to shares of common stock of the Company in connection with the Company's Initial Public Offering in 2018, and (ii) vesting of shares of restricted stock issued to the reporting person by the Company pursuant to the reporting person's employment agreement with the Company. Read SEC document |
| May 31, 2020 Filed Jun 2, 2020 17:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005338 · marketforms-48933.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| May 31, 2020 Filed Jun 2, 2020 17:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,492 | $4.87 | $31,616.04 |
DisclosureSEC source: 0001214659-20-005338 · marketforms-48933.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,964 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| May 31, 2020 Filed Jun 2, 2020 17:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005338 · marketforms-48933.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:16 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003146 · marketforms-48494.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:16 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 99 | $2.19 | $216.81 |
DisclosureSEC source: 0001214659-20-003146 · marketforms-48494.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,884 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:16 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003146 · marketforms-48494.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 16:46 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001214659-20-002749 · marketforms-48348.xml · derivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 19:37 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002183 · marketforms-48059.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,572 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 19:37 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 4,729 | $3.73 | $17,639.17 |
DisclosureSEC source: 0001214659-20-002183 · marketforms-48059.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,654 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 19:37 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002183 · marketforms-48059.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 14:04 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000018 · marketforms-47053.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 14:04 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 329 | $5.82 | $1,914.78 |
DisclosureSEC source: 0001214659-20-000018 · marketforms-47053.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,656 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 14:04 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000018 · marketforms-47053.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2019 Filed Feb 26, 2020 16:20 UTC Amendment | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 149 | $5.82 | $867.18 |
DisclosureSEC source: 0001214659-20-001882 · marketforms-47921.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,811 F1 · shares: This amendment is being filed solely to amend the number of withheld shares due to a mistake in the number of shares withheld upon vesting of RSUs as reported in the original Form 4 filed on January 2, 2020. Read SEC document |
| November 30, 2019 Filed Dec 2, 2019 16:56 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-007536 · marketforms-46719.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,144 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| November 30, 2019 Filed Dec 2, 2019 16:56 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 14,572 | $7.79 | $113,515.88 |
DisclosureSEC source: 0001214659-19-007536 · marketforms-46719.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,656 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| November 30, 2019 Filed Dec 2, 2019 16:56 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-007536 · marketforms-46719.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 677,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 30, 2019 Filed Feb 26, 2020 16:05 UTC Amendment | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,597 | $7.79 | $51,390.63 |
DisclosureSEC source: 0001214659-20-001860 · marketforms-47922.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,631 F1 · shares: This amendment is being filed solely to amend the number of withheld shares due to a mistake in the number of shares withheld upon vesting of RSUs as reported in the original Form 4 filed on December 2, 2019. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006187 · marketforms-45873.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 150 | $3.18 | $477.00 |
DisclosureSEC source: 0001214659-19-006187 · marketforms-45873.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,656 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006187 · marketforms-45873.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2019 Filed Sep 3, 2019 18:09 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-005619 · marketforms-45657.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,716 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| August 31, 2019 Filed Sep 3, 2019 18:09 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,676 | $3.80 | $25,368.80 |
DisclosureSEC source: 0001214659-19-005619 · marketforms-45657.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,477 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| August 31, 2019 Filed Sep 3, 2019 18:09 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-005619 · marketforms-45657.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 14, 2019 Filed Aug 20, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $3.65 | $3,650.00 |
DisclosureSEC source: 0001214659-19-005387 · marketforms-45524.xml · nonDerivative · entry 6 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,581 Read SEC document |
| August 14, 2019 Filed Aug 20, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $3.70 | $3,697.00 |
DisclosureSEC source: 0001214659-19-005387 · marketforms-45524.xml · nonDerivative · entry 5 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,581 Read SEC document |
| August 13, 2019 Filed Aug 20, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $4.05 | $4,045.00 |
DisclosureSEC source: 0001214659-19-005387 · marketforms-45524.xml · nonDerivative · entry 4 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,581 Read SEC document |
| August 09, 2019 Filed Aug 20, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 2,000 | $4.00 | $7,990.00 |
DisclosureSEC source: 0001214659-19-005387 · marketforms-45524.xml · nonDerivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,581 Read SEC document |
| August 09, 2019 Filed Aug 20, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $3.93 | $3,925.00 |
DisclosureSEC source: 0001214659-19-005387 · marketforms-45524.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,581 Read SEC document |
| August 09, 2019 Filed Aug 20, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 2,000 | $3.84 | $7,680.00 |
DisclosureSEC source: 0001214659-19-005387 · marketforms-45524.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,581 Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-004459 · marketforms-45277.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,320 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 154 | $4.20 | $646.80 |
DisclosureSEC source: 0001214659-19-004459 · marketforms-45277.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,581 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-004459 · marketforms-45277.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-003979 · marketforms-45122.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,288 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,780 | $3.72 | $25,221.60 |
DisclosureSEC source: 0001214659-19-003979 · marketforms-45122.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,406 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-003979 · marketforms-45122.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 31, 2019 Filed Apr 1, 2019 16:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-002418 · marketforms-44722.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,649 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.